Oral News and Research

RSS

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Boehringer Ingelheim today announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus.

9 Dec 2011

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

NSU's College of Dental Medicine to provide care for persons with special needs

Nova Southeastern University's (NSU) College of Dental Medicine recently received a two-year, $437, 616 grant from the DentaQuest Foundation to train practicing dentists in Florida to provide care for persons with special needs.

8 Dec 2011

Lawmakers debate value of cameras in the courtroom

A Democratic senator dismissed those fears Tuesday, saying cameras would not cheapen the high court's proceedings. "I'm trying to picture Ruth Bader Ginsburg turning into Judge Judy. I just don't think it's going to happen," Sen. Amy Klobuchar (D-Minn.) said during a hearing on the subject Tuesday.

8 Dec 2011

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

8 Dec 2011

Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting

Inviragen, Inc. presented results of the Phase 1 clinical trial of DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting today.

8 Dec 2011

Cautious Patient Foundation introduces new national YDA program

Known as "Your Doctor's Advice" (YDA), the program provides an easy-to-use, high-tech solution to a major contributing factor in patient noncompliance and poor medical outcomes.

7 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

Scientists help uncover evolutionary history of TAS2R38 bitter taste receptor gene

Long the bane of picky eaters everywhere, broccoli's taste is not just a matter of having a cultured palate; some people can easily taste a bitter compound in the vegetable that others have difficulty detecting. Now a team of Penn researchers has helped uncover the evolutionary history of one of the genes responsible for this trait.

7 Dec 2011

Milk powder outperforms lower-dose therapy for treatment of food allergies

A small study by researchers at the Johns Hopkins Children's Center and Duke University shows that eating higher doses of milk protein in the form of dry powder substantially outperforms lower-dose therapy — a few drops of liquid milk extract under the tongue — for treatment of food allergies.

7 Dec 2011

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

BioLineRx announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.

6 Dec 2011

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

5 Dec 2011

Hi-Tech Pharmacal second quarter net sales increase 27% to 56,875,000

Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal second quarter ended October 31, 2011.

5 Dec 2011

Zalicus commences Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160 (formerly NMED-160), a novel oral N-type calcium channel blocker.

5 Dec 2011

CTI seeks license to market Pixuvri in the E.U. for treatment of NHL

Cell Therapeutics, Inc. announced today an update on the status and progress of its European marketing authorization application for Pixuvri.

5 Dec 2011

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

When the American Society of Hematology convenes its 53rd Annual Meeting and Exposition on Dec. 10-13 in San Diego, Calif., researchers from Moffitt Cancer Center will break a new record for Moffitt participants with one plenary presentation, 16 oral presentations and more than 50 poster presentations on new research results in a variety of meeting programs that focus on blood cancer basic science and clinical applications, including bone marrow transplantation and clinical trials results.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

FDA approves Mylan's Tranexamic Acid Injection ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials.

3 Dec 2011

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).

3 Dec 2011

Oral News and Research

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

NSU's College of Dental Medicine to provide care for persons with special needs

Lawmakers debate value of cameras in the courtroom

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting

Cautious Patient Foundation introduces new national YDA program

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

Scientists help uncover evolutionary history of TAS2R38 bitter taste receptor gene

Milk powder outperforms lower-dose therapy for treatment of food allergies

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Hi-Tech Pharmacal second quarter net sales increase 27% to 56,875,000

Zalicus commences Z160 Phase 1 clinical trial for pain

CTI seeks license to market Pixuvri in the E.U. for treatment of NHL

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

FDA approves Mylan's Tranexamic Acid Injection ANDA

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News